Catalyst Pharmaceuticals Earns Top Ranking on *Forbes* 2026 List of America’s Most Successful Small‑Cap Companies

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a biopharmaceutical company headquartered in Coral Gables, Florida, announced it has been named to *Forbes’* prestigious *2026 List of America’s Most Successful Small‑Cap Companies*, ranking **11th out of the top 100** publicly traded small‑cap firms in the U.S.  The annual Forbes list recognizes small‑cap companies (with market values between $300 million and $5 billion) that have delivered strong financial performance, including positive sales growth over the past year and share prices above $5. The ranking is based on key metrics such as earnings growth, sales growth, return on equity, and total stock return over a five‑year period, with extra weight given to recent performance data through October 31, 2025  Rich Daly, President and CEO of Catalyst, expressed pride in the company’s inclusion, highlighting the dedication of its employees and its commitment to serving rare disease patient communities. The company focuses on in‑licensing, developing, and commercializing medicines for patients living with rare and difficult‑to‑treat conditions, and strives to ensure broad access to its therapies through comprehensive support services  Catalyst has previously been recognized by Forbes on this list in prior years and was featured on the 2025 Deloitte Technology Fast 500™ as one of North America’s fastest‑growing companies. Investors and healthcare stakeholders alike view the ranking as validation of Catalyst’s growth strategy and operational achievements. #CatalystPharma #ForbesSmallCap2026 #BiopharmaSuccess #RareDiseaseInnovation #SlimScan #GrowthStocks #CANSLIM